If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Quality, Compliance and Regulatory » Government Affairs and Public Policy
Download FREE Excerpt
17 Info Graphics
19 Data Graphics
3 Best Practices
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
The influence of the Centers for Medicare and Medicaid Services (CMS) on healthcare policy and reimbursement is increasing as the US population ages and healthcare reform unfolds. Federal, state and local government healthcare spending is projected to be 50 percent of national health expenditures by 2021. Consequently, the importance of understanding, translating, and engaging CMS and other influential government agencies/groups will only grow.
Best Practices, LLC conducted this research to help biopharmaceutical executives in Government Affairs, Public Policy, Managed Markets and other groups formulate a strategic approach for optimizing engagement with CMS and the ecosystem of agencies and groups that shape U.S. healthcare guidelines and reimbursement policy. The study identifies current trends and future directions in structure, alignment, and information exchange across key functional groups in the biopharmaceutical and medical device sectors that interact with the agencies and committees that influence the government healthcare sector.
The study includes three segments: a Large Pharma Segment, a Mid-Cap Pharma Segment, and an Emerging Pharma segment.
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Chemical; Biopharmaceutical; Clinical Research; Laboratories
Amylin; Astellas; AstraZeneca; Bayer; Boehringer Ingelheim; Cubist; Daiichi-Sankyo; GE Healthcare; Genentech; GlaxoSmithKline; IDEA Pharma; Integrated Diagnostics; Merck; Millenium; Novo Nordisk; ProStraken; Purdue; Sagent; Sanofi; Shionogi; Shire; Smith & Nephew